EUVIMEDEUVIMED entdecken
Open Access

Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases

Ana C Puhl, Sean Ekins

GEN Biotechnology · 2022

DOI: 10.1089/genbio.2021.0013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift GEN Biotechnology, 2022. Verfasst von Ana C Puhl und 1 weiteren Autor:innen. Beteiligte Einrichtung: Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the increasing interest in developing gene therapies for rare diseases, it is easy to overlook that there are numerous rare lysosomal storage diseases (LSD) with treatments that have been approved by regulatory agencies in the United States and Europe. These primarily consist of enzyme replacement therapies (ERT), which are recombinant human proteins that are delivered for the life of the patient via different routes and may have distinct safety and distribution advantages over gene therapies. The research and development of ERT is a lengthy and expensive process, which is usually performed in academic laboratories before transfer to pharmaceutical companies and is hence a process ripe for disruption. There may still be considerable scientific and investment potential for ERT, however we need to develop a pipeline of proteins analogous to what has been created in some open science efforts as well as apply technologies to decrease manufacturing costs. In this Perspective, we illustrate the opportunity to fill the rare LSD treatment gap with ERTs while gene therapies are in development for these life-shortening diseases.

Schlagwörter

Stichwörter der Autor:innen

enzyme replacement therapylysosomal storage diseaseslysosomespipelinerare diseases

Autor:innen und Institutionen

  • Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.

Förderung

  • NINDS NIH HHS

Zitieren

APA

Puhl, A. C., & Ekins, S. (2022). Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases. GEN Biotechnology. https://doi.org/10.1089/genbio.2021.0013

Vancouver

Puhl AC, Ekins S. Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases. GEN Biotechnology. 2022. doi:10.1089/genbio.2021.0013

BibTeX
@article{Puhl2022,
  author = {Puhl, Ana C and Ekins, Sean},
  title = {Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases},
  journal = {GEN Biotechnology},
  year = {2022},
  doi = {10.1089/genbio.2021.0013}
}
Kostenlos starten →